鐮狀細胞貧血治療市場規模、佔有率、成長分析、按治療、按最終用途、按地區 - 行業預測，2024-2031 年

Sickle Cell Disease Treatment Market Size, Share, Growth Analysis, By Treatment (Blood Transfusion, Bone Marrow Transplant), By End-use (Hospitals, Specialty Clinics), By Region - Industry Forecast 2024-2031

出版日期: 2024年12月20日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

鐮狀貧血治療的全球市場規模預計將在2022 年達到21 億美元，從2023 年的25.5 億美元成長到2031 年的120.3 億美元，預計在預測期內（2024-2031 年）將以年複合成長率成長。

全球鐮狀細胞病患疾病的上升預計將極大地推動對有效治療的需求，特別是在遺傳傾向和意識較低的地區，例如非洲、中東和印度。增加對新治療方法研究的投資為該領域的公司提供了機會。此外，政府和非營利組織旨在提高意識的支持努力也可能擴大市場前景。從長遠來看，創新藥物的湧入和不斷擴大的治療管道可能會推動市場成長。然而，新治療方法的安全性問題、基因療法複雜的法規環境以及持續缺乏認知等挑戰可能會阻礙 2031 年後全球鐮狀細胞疾病治療市場的進展。

北美洲
- 美國
- 加拿大
歐洲
- 英國
- 德國
- 西班牙
- 法國
- 義大利
- 其他歐洲國家地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東/非洲
- 海灣合作理事會國家
- 南非
- 其他中東/非洲

競爭資訊

前5名企業對比
主要企業市場定位（2023年）
主要市場參與者所採取的策略
近期市場趨勢
公司市場佔有率分析（2023）
主要企業簡介
- 公司簡介
- 產品系列分析
- 按細分市場分類的佔有率分析
- 收益與前一年同期比較（2021-2023）

主要企業簡介

Novartis AG
Emmaus Medical, Inc.
Addmedica
Medunik USA
Global Blood Therapeutics, Inc.
Bristol Myers Squibb Co.
Sanofi SA
Bluebird Bio
Pfizer Inc.
Aruvant Sciences, Inc.
Glycomimetics, Inc.
Editas Medicine, Inc.
CRISPR Therapeutics
F. Hoffmann-La Roche Ltd
Janssen Pharmaceuticals
Merck & Co., Inc.
AstraZeneca
Gilead Sciences
Vertex Pharmaceuticals
Hemanext

結論和建議

簡介目錄

Product Code: SQMIG35D2091

Global Sickle Cell Disease Treatment Market size was valued at USD 2.10 billion in 2022 and is poised to grow from USD 2.55 billion in 2023 to USD 12.03 billion by 2031, growing at a CAGR of 4.1 % in the forecast period (2024-2031).

The rising global incidence of sickle cell disease is expected to significantly drive demand for effective treatments, particularly in regions like Africa, the Middle East, and India, where genetic predisposition and limited awareness prevail. Greater investment in research for novel therapies presents opportunities for companies in this sector. Additionally, supportive initiatives from governments and non-profits aimed at increasing awareness will broaden market prospects. The influx of innovative drugs and expanded treatment pipelines is set to enhance market growth in the long term. However, challenges such as safety concerns with new treatments, a complex regulatory environment for genetic therapies, and ongoing awareness deficits may hinder progress in the global sickle cell disease treatment market through 2031 and beyond.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Sickle Cell Disease Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Sickle Cell Disease Treatment Market Segmental Analysis

Global Sickle Cell Disease Treatment Market is segmented by Treatment, End-use and region. Based on Treatment, the market is segmented into Blood Transfusion, Bone Marrow Transplant, Pharmacotherapy (Hydroxyurea, Branded Products). Based on End-use, the market is segmented into Hospitals, Specialty Clinics, Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Sickle Cell Disease Treatment Market

The increasing prevalence of sickle cell disease is a significant driver for the global treatment market. Factors such as genetic factors and inadequate early detection have contributed to a sharp rise in cases worldwide. Regions such as Africa, India, and the Middle East are projected to have particularly high rates of sickle cell disease, presenting lucrative opportunities for treatment providers in these areas. As awareness and the need for effective treatment options grow, these markets are becoming increasingly attractive for healthcare companies focused on addressing the challenges posed by this condition and improving patient outcomes.

Restraints in the Global Sickle Cell Disease Treatment Market

A significant restraint in the Global Sickle Cell Disease Treatment market is the limited awareness and diagnosis among the public. Many individuals remain unaware of the symptoms associated with sickle cell disease, leading to delays in seeking medical attention and subsequent diagnosis. Furthermore, the inadequate diagnostic infrastructure in various regions exacerbates this issue, resulting in numerous cases either going undetected or being diagnosed too late for effective treatment. This combination of lack of awareness and insufficient diagnostic capabilities hinders the overall demand for sickle cell disease therapies, posing a challenge for growth in the treatment market moving forward.

Market Trends of the Global Sickle Cell Disease Treatment Market

The Global Sickle Cell Disease Treatment market is witnessing a burgeoning trend centered around collaborative efforts aimed at enhancing treatment accessibility. Varying availability of therapies across regions has hindered the adoption of innovative treatments, prompting partnerships among governments, non-profit organizations, and healthcare companies. These collaborations seek to improve the affordability and accessibility of therapies, thereby promoting patient access and increasing market penetration. As stakeholders unite to address the disparities in treatment availability, the market is poised for significant growth, leading to improved patient outcomes and revenue generation in the long run, while fostering a more equitable healthcare landscape for sickle cell disease management.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Driver & Opportunities
- Restraints & Challenges
Porters Analysis & Impact
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2023
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Technological Advancement
Regulatory Landscape
Case Studies

Global Sickle Cell Disease Treatment Market Size by Treatment & CAGR (2024-2031)

Market Overview
Bone Marrow Transplant
Blood Transfusion
Pharmacotherapy
- Hydroxyurea
- Branded Products

Global Sickle Cell Disease Treatment Market Size by End-use & CAGR (2024-2031)

Market Overview
Hospitals
Specialty Clinics
Others

Global Sickle Cell Disease Treatment Market Size & CAGR (2024-2031)

North America, (Treatment, End-use)
- US
- Canada
Europe, (Treatment, End-use)
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific, (Treatment, End-use)
- China
- India
- Japan
- South Korea
- Rest of Asia Pacific
Latin America, (Treatment, End-use)
- Brazil
- Rest of Latin America
Middle East & Africa, (Treatment, End-use)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2023
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Emmaus Medical, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Addmedica
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Medunik USA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Global Blood Therapeutics, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol Myers Squibb Co.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi SA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bluebird Bio
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aruvant Sciences, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Glycomimetics, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Editas Medicine, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
CRISPR Therapeutics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche Ltd
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Janssen Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gilead Sciences
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Vertex Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hemanext
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments